| Literature DB >> 25656928 |
Yeng Chen1,2, Choon K Chan3, Jesinda P Kerishnan4, Yee L Lau5, Yin-Ling Wong6, Subash Cb Gopinath7,8.
Abstract
BACKGROUND: Plasmodium knowlesi was identified as the fifth major malaria parasite in humans. It presents severe clinical symptoms and leads to mortality as a result of hyperparasitemia in a short period of time. This study aimed to improve the current understanding of P. knowlesi and identify potential biomarkers for knowlesi malaria.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25656928 PMCID: PMC4336705 DOI: 10.1186/s12879-015-0786-2
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Figure 1Representative 2-DE serum protein profiles for (a) control (b) -infected individuals. Unfractionated serum samples from patients and controls were subjected to 2-DE and silver stained. Protein spots were compared and analysed using PD-Quest™ 2-D gel analysis software (version 8.0.1, Bio-Rad).
The relative expression of host specific proteins among the sera of malaria patients
|
|
|
|---|---|
| 1. Alpha-2-HS glycoprotein (AHSG) | 1.28 |
| 2. Serotransfererrin (TF) | 1.15 |
| 3. Complement C3c (C3) | 8.99 |
| 4. Hemopexin (HPX) | 1.60 |
| 5. Zinc-2-alpha glycoprotein (ZAG1) | 3.40 |
| 6. Haptoglobin (HAP) | 0.42 |
| 7. Apolipoprotein A-I (Apo-A1) | 0.34 |
| 8. Alpha-1-B-glycoprotein (A1BG) | 0.53 |
Fold change measures the degree of change in the protein of the P. knowlesi-infected individuals (n = 9), compared to normal controls (n = 23). This is measured by dividing the average spot intensity in the infected persons by the average spot intensity in the controls.
Host antigenic proteins show on the 2-DE immunoblotted nitrocellulose membrane
|
|
| ||||
|---|---|---|---|---|---|
|
|
|
|
|
| |
| 1. AHSG | - | / | - | / | / |
| 2. TF | - | - | - | / | - |
| 3. C3 | - | - | - | / | / |
| 4. HPX | - | - | - | / | - |
| 5. ZAG1 | - | - | - | / | / |
| 6. HAP | - | - | - | - | / |
| 7. Apo-A1 | - | / | - | / | / |
| 8. A1BG | - | / | - | / | / |
| 9. HRG | - | - | - | - | / |
/Proteins of the patients or normal pooled serum recognized by the primary antibody.
-Proteins of the patients or normal pooled serum not recognized by the primary antibody.
Antigenic proteins show on the 2-DE immunoblotted nitrocellulose membrane
|
|
| ||||
|---|---|---|---|---|---|
|
|
|
|
|
| |
| 1. K15 | - | - | - | (/) | - |
| 2. K16 | - | - | - | (/) | - |
| 3. K17 | - | - | - | - | / |
| 4. K23 | - | - | - | - | / |
| 5. K26 | - | - | - | - | / |
| 6. K28 | - | - | - | (/) | - |
| 7. K29 | - | - | - | (/) | - |
| 8. K30 | - | - | - | (/) | - |
| 9. K32 | - | - | - | / | / |
| 10. K33 | - | - | - | / | / |
| 11. K38 | - | - | - | (/) | - |
(/)Antigens specifically detected in the knowlesi serum.
/Proteins of the patients or normal pooled serum recognized by the primary antibody.
-Proteins of the patients or normal pooled serum not recognized by the primary antibody.
Mass spectrometric identification of host-specific protein spot clusters from serum protein profiles using MASCOT search engine and NCBI database
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| 1. Chain C, Human Complement Component C3c (C3) | gi|78101271 | 4.79 | 40217 | 10% | 218 | 6 | 1.8e−015 |
| 2. Transferrin (TF) | gi|553788 | 6.00 | 55233 | 13% | 82 | 10 | 0.082 |
| 3. Chain A, Crystal Structure Of Lipid-Free Human Apolipoprotein A-I (ApoA1) | gi|90108664 | 5.27 | 28061 | 62% | 357 | 26 | 2.3e−029 |
| 4. Leucine-rich α2-glycoprotein precursor [Homo sapiens] (LRG1) | gi|16418467 | 6.45 | 38382 | 31% | 358 | 16 | 1.8e−029 |
| 5. Hemopexin, isoform CRA_d [Homo sapiens] (HPX) | gi|119589127 | 6.24 | 43781 | 13% | 112 | 8 | 7.3e−005 |
| 6. α1-B-glycoprotein (A1BG) | gi|69990 | 5.65 | 52479 | 39% | 449 | 20 | 1.5e−038 |
| 7. α2-HS-glycoprotein, isoform CRA_b [Homo sapiens] (AHSG) | gi|119598594 | 4.81 | 23148 | 6% | 121 | 2 | 9.2e−006 |
| 8. Haptoglobin [Homo sapiens] (HAP) | gi|3337390 | 6.14 | 38722 | 28% | 202 | 15 | 7.3e−014 |
| 9. Histidine-rich glycoprotein precursor [Homo sapiens] (HRG) | gi|4504489 | 7.09 | 60510 | 13% | 114 | 10 | 4.6e−005 |
| 10. Chain B, Human Zinc-α2-glycoprotein (ZAG1) | gi|4699583 | 5.70 | 31854 | 51% | 523 | 22 | 5.8e−046 |
| 11. Fibrinogen gamma chain (FGG) | gi|930064 | 6.49 | 24337 | 45% | 56 | 10 | 33 |
Mass spectrometric identification of unknown protein spot clusters from serum protein profiles using MASCOT search engine, NCBI database and Plasmo DB
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Plasmodium_knowlesi_strain_H | product = hypothetical protein, conserved in Apicomplexan s | psu|PKH_030860 | K15 | 8.42 | 57570 | 16% | 37 | 8 | 1.1 |
| Plasmodium_knowlesi_strain_H | product = conserved Plasmodium protein, unknown function | psu|PKH_050250 | K16 | 9.20 | 52407 | 1% | 26 | 2 | 13 |
| Plasmodium_knowlesi_strain_H | product = dynein light chain 1, putative | location = Pk_stra | psu|PKH_050850 | K17 | 8.75 | 23061 | 34% | 34 | 7 | 2.1 |
| Plasmodium_knowlesi_strain_H | product = conserved Plasmodium protein, unknown function | | psu|PKH_093010 | K23 | 5.08 | 32237 | 34% | 46 | 10 | 0.13 |
| Plasmodium_knowlesi_strain_H | product = translation intiation factor IF-2 | location = Pk_s | psu|PKH_050380 | K24 | 8.77 | 137165 | 5% | 28 | 12 | 7.7 |
| Plasmodium_knowlesi_strain_H | product = conserved Plasmodium protein | PKH_050250 | K26 | 9.20 | 52407 | 1% | 29 | 2 | 6.9 |
| Plasmodium_knowlesi_strain_H | product = conserved Plasmodium protein, unknown function | psu|PKH_091010 | K28 | 8.32 | 20628 | 8% | 38 | 3 | 0.82 |
| Plasmodium_knowlesi_strain_H | product = conserved Plasmodium protein, unknown function | psu|PKH_050250 | K29 | 9.20 | 52407 | 1% | 15 | 2 | 1.6e+002 |
| Plasmodium_knowlesi_strain_H | product = conserved Plasmodium protein, unknown function | psu|PKH_091010 | K30 | 8.32 | 20628 | 8% | 32 | 3 | 8.32 |
| Plasmodium_knowlesi_strain_H | product = SOH1 homologue, putative | location = Pk_strainH_ch | psu|PKH_126910 | K32 | 6.90 | 16303 | 20% | 42 | 9 | 0.37 |
| Plasmodium_knowlesi_strain_H | product = hypothetical protein, conserved in Apicomplexan s | psu|PKH_031640 | K33 | 9.43 | 9570 | 24% | 25 | 3 | 18 |
| Plasmodium_knowlesi_strain_H | product = dihydrolipoamide dehydrogenase, putative | ocate | psu|PKH_051660 | K37 | 9.21 | 74131 | 1% | 16 | 2 | 1.2e+002 |
| Plasmodium_knowlesi_strain_H | product = conserved Plasmodium protein, unknown function | psu|PKH_050250 | K38 | 9.20 | 52407 | 1% | 31 | 2 | 4.4 |
Figure 2Western blot results following 2-DE. (a) normal pooled sera probed with normal pooled sera, (b) normal pooled sera probed with P. knowlesi pooled sera, (c) P. knowlesi pooled sera probed with normal pooled sera, (d) P. knowlesi pooled sera probed with P. knowlesi pooled sera, Unfractionated, pooled serum samples from patients and normal controls were subjected to 2-DE, transferred onto nitrocellulose membranes, and probed with pooled sera (as primary antibody) followed by monoclonal anti-human IgM-HRP (as secondary antibody).
Figure 3Western blot of pooled sera probed with pooled sera. Unfractionated, pooled serum samples from patient is subjected to 2-DE, transferred onto nitrocellulose membranes, and probed with pooled sera (as primary antibody) followed by monoclonal anti-human IgM-HRP (as secondary antibody).
Functional enrichment classification of identified host-specific proteins using DAVID bioinformatics tool
|
|
|
|
| ||
|---|---|---|---|---|---|
| Biological process | Regulation of response to external stimulus | 2.3 | 3 (27.27) | AHSG, C3, HRG | 4.69e-3 |
| Cellular iron ion homeostasis | 2.13 | 3 (27.27) | HAP, HPX, TF | 1.81e-4 | |
| Iron ion homeostasis | 2.13 | 3 (27.27) | HAP, HPX, TF | 2.45e-4 | |
| Cellular di-, tri-valent inorganic cation homeostasis | 2.13 | 3 (27.27) | HAP, HPX, TF | 9.34e.3 | |
| Di-, tri-valent inorganic cation homeostasis | 2.13 | 3 (27.27) | HAP, HPX, TF | 1.03e-2 | |
| Cellular cation homeostasis | 2.13 | 3 (27.27) | HAP, HPX,TF | 1.16e-2 | |
| Molecular function | Endopeptidase inhibitor activity | 2.3 | 3 (27.27) | AHSG,C3, HRG | 3.32e-3 |
| Peptidase inhibitor activity | 2.3 | 3 (27.27) | AHSG, C3, HRG | 3.69e-3 | |
| Enzyme inhibitor activity | 2.3 | 3 (27.27) | AHSG, C3, HRG | 1.11e-2 | |
| Cellular component | Extracellular region | 8.11 | 11 (100) | A1BG, AHSG, APOA1, AZGP1, C3, FGG, HAP, HPX, HRG, LRG1, TF | 2.66e-11 |
| Secretory granule | 2.31 | 4 (36.36) | APOA1, FGG, HRG, TF | 3.06e-4 | |
| Cytoplasmic membrane-bounded vesicle | 2.31 | 4 (36.36) | APOA1, FGG, HRG, TF | 7.58e-3 | |
| Membrane-bounded vesicle | 2.31 | 4 (36.36) | APOA1, FGG, HRG, TF | 8.29e-3 | |
| Cytoplasmic vesicle | 2.31 | 4 (36.36) | APOA1, FGG, HRG, TF | 1.16e-2 |
+The classification stringency was set to high.
Figure 4Interaction networks of identified host specific proteins using STRING v9.1. STRING database is a curated knowledge database that relies on various evidences from high-throughput proteomic, genomic and co-expression studies. The predicted functions of proteins are shown.